Cryoport Third Quarter 2026 Earnings Call - CRYOPORT INC

Explicit Guidance:

• Full-Year 2026 Revenue: Raised to $197 million to $199 million, representing a midpoint increase of ~$4 million and implying a 12% year-over-year growth rate.
• Q4 2026 Revenue: Implied guidance of $50 million to $52 million (based on Q1-Q3 performance and full-year outlook).
• Long-Term Margin Targets: Management reiterates a long-term target of 55% gross margins and 30% adjusted EBITDA margins, with expansion expected in 2027 and beyond as facility utilization increases.
• EBITDA Trajectory: Expects continued improvement in adjusted EBITDA and operating leverage, building on the second consecutive quarter of positive adjusted EBITDA ($1.1M in Q3 2026).

Business-Segment Outlook:

• Cell and Gene Therapy Services: Revenue from commercial clients is currently growing 20% YoY, representing 20% of total revenue; combined with clinical trials (47% of revenue), this segment is the primary growth driver.
• MVE (Cryogenic Systems): Expected to deliver mid-single to mid-digit revenue growth on a continuing basis. Animal health and fusion line freezers are driving strong demand.
• China Market: Revenue expected to remain stable at 3–4% of total, with no significant growth anticipated; China operations function as both an internal supplier for other sites and an external supplier for animal health.
• Bioservices & Biostorage: Expects to maintain >20% year-over-year growth long-term. New sterile kitting operations are ramping in Belgium, with Houston expansion coming next year.
• IntegraCell: Currently in early stages with multiple clients; adding cryopreservation activities at Morris Plains next year to support community care expansion.

Market and Competitive Outlook:

• Clinical Pipeline: Record 788 clinical trials active (net increase of 43 YoY), with 99 in Phase 3.
• Regulatory Activity: Outlook for the remainder of the year includes five possible BLA-MAA filings, two potential new therapy approvals (SELEX in November, Capricor in December), and one supplemental approval for geographic expansion.
• Commercial Launches: Two additional therapies expected to commercialize in 2026. A first-in-class autoimmune disease therapy is anticipated for approval in early 2027.
• Industry Growth: Citing Alliance for Regenerative Medicine data, the cell and gene therapy market is projected to grow at a 34% CAGR from $10.2B in 2025 to ~$60B in 2031.

Macro / Industry Outlook:

• Funding Environment: Observing a rebound in capital availability and "deeper pockets" following consolidation (e.g., Gilead's acquisition of Arcelix), facilitating faster commercialization.
• PDUFA Dates: Specific regulatory milestones are tracked, with two major PDUFA dates scheduled for the fourth quarter of the current fiscal year.
• External Factors: Management notes "external things," including potential government-related events, as variables embedded in the conservative guidance stance.

Strategic Initiatives:

• Global Supply Chain Expansion: Capacity additions in Paris, France (ISO 21973 certified) and Santa Ana, California are expected to be substantially complete in 2027, adding bioservices capabilities.
• Operational Synergies: New facilities will enable a full end-to-end platform (biologistics + bioservices), expected to drive significant operating leverage and margin expansion in 2027.
• CryoGene Expansion: New "Cryogenic Technical Services" division launched; additional sites planned for Moffitt Cancer Center in Tampa, expected to be operational later in 2027.
• Pathway to Profitability: Continued focus on cost control and utilizing new capacity to transition from growth investments to sustained profitability.

Risks and Headwinds to Outlook:

• Guidance Conservatism: Q4 and full-year guidance is described as "prudent" and "conservative," potentially excluding revenue from new approvals due to typical ramp-up times.
• Therapy Ramp Timing: New approvals generally take time to scale; revenue impacts from the two upcoming Q4 approvals may not be fully reflected in current guidance.
• Regulatory/Clinical Delays: Five filings originally expected in 2026 were pushed into 2027, illustrating potential timing variability.
• Macro/Government Uncertainty: Management cites potential government-related events as a reason for maintaining a conservative stance on Q4 sequencing.

Management Tone on the Future:

• Confidence: Describes the outlook as "bullish" and the future as "really, really bright," citing strong momentum and broad-based strength across services and products.
• Strategic Position: Expresses pride in the first-mover leadership position, specifically regarding ISO 21973 certification and the integrated supply chain ecosystem.
• Execution: Highlights a shift from building capacity to realizing operating leverage, with expectations for further margin expansion as facilities reach full utilization in 2027.

Miscellaneous:

• Discontinued Operations: Financials for CryoPDP (sold to DHL in June 2025) are now classified as discontinued operations; all guidance refers to continuing operations.
• Certifications: Paris Global Supply Chain Center achieved ISO 9001 and ISO 21973 certifications, receiving the Healthcare and Pharmaceutical Supply-Chain Excellence Award.